RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia - Test2 - elhamkhani - TriplyDB

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

http://www.wikidata.org/entity/Q29617201

about

The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer The basal transcription machinery as a target for cancer therapy Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability Structural insights into recognition of acetylated histone ligands by the BRPF1 bromodomain Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting Brd4 and JMJD6-associated anti-pause enhancers in regulation of transcriptional pause release Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer SYK is a critical regulator of FLT3 in acute myeloid leukemia A decade of exploring the cancer epigenome - biological and translational implications Small-molecule inhibition of BRDT for male contraception.Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System Tumors The Impact of External Factors on the Epigenome: In Utero and over Lifetime DNA Methylation and Chromatin Remodeling: The Blueprint of Cancer Epigenetics Epigenetic regulators and their impact on therapy in acute myeloid leukemia Genetics and biology of pancreatic ductal adenocarcinoma Regulation of MYC gene expression by aberrant Wnt/β-catenin signaling in colorectal cancer Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance Origins, genetic landscape, and emerging therapies of small cell lung cancer Linking epithelial-to-mesenchymal-transition and epigenetic modifications Bromodomain proteins in HIV infection Mutual relationships between transcription and pre-mRNA processing in the synthesis of mRNA Functional genomics lead to new therapies in follicular lymphoma Epigenetics: the fine-tuner in inflammatory bowel disease?Functional interactions among members of the MAX and MLX transcriptional network during oncogenesis Recent progress toward epigenetic therapies: the example of mixed lineage leukemia Epigenetic regulators as promising therapeutic targets in acute myeloid leukemia Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy Chromatin targeting drugs in cancer and immunity Synthetic lethal screens as a means to understand and treat MYC-driven cancers Hijacked in cancer: the KMT2 (MLL) family of methyltransferases Proteomics in epigenetics: new perspectives for cancer research Protein lysine acetylation by p300/CBP Epigenetic plasticity: a central regulator of epithelial-to-mesenchymal transition in cancer Getting up to speed with transcription elongation by RNA polymerase II Small-molecule inhibitors of the Myc oncoprotein Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity Benzodiazepines and benzotriazepines as protein interaction inhibitors targeting bromodomains of the BET family

P2860

Q21128760-0BADDD45-66EF-4A19-83F2-9682E43A0219 Q21246017-C4A28451-AE6F-4126-9F78-386A89D45109 Q24293271-A4AE7867-2050-48B6-BEF4-0E387EB44347 Q24296476-4360851C-AF5F-4F7E-B682-99DD8E4F835A Q24305108-D77EAD86-2E9C-4086-8FDF-18B1BE86F424 Q24308867-9D5CB345-F4E5-46A1-976C-936FDBDCA865 Q24315005-85205D99-6AED-4954-AC3A-1E7E78ABF2B1 Q24337204-D5A44A21-8CA6-438A-8641-CDF5CF50F569 Q24337247-5F0C74F3-9BDB-499F-9F2B-776D6F373763 Q24614467-49F49518-7CA7-4C3B-B9C9-BB790438FD25 Q24616901-437392DA-9DAF-4FB1-BB4D-B644B1639FE2 Q26744080-4AFF0653-4303-48E8-A04B-9BB8C0E64D99 Q26744268-C8EC887D-EA54-4E4A-9D67-10017BC1D059 Q26746703-5AC8CF89-AC40-46D5-B09B-FD4F697F344C Q26749421-2C9FA3CF-9942-4DA7-BF06-49CFCACD5EA5 Q26765402-C4C3C17A-32BD-40A3-B382-AEED5951F912 Q26765438-C6260480-A129-4A9F-BBE0-9285B9DB5745 Q26775423-21D6AE0E-8891-4D07-8A87-CED2D0AB5156 Q26776393-9857296C-69DA-45BB-BDE7-84F2C9DBF611 Q26798218-38159112-7044-42E5-9025-089D080998BF Q26824575-A941DF06-F9D1-48EB-AE87-E5BC06647680 Q26829860-11099C29-7776-4960-818E-8536FAC622F6 Q26851218-34F69BA6-9EFF-4F98-BC86-45CC7E9643EC Q26852415-92F19D18-DA0A-4BC9-A17C-B580428A6981 Q26853555-1CF0F3A2-DE8C-4D50-BECF-796AFD16CCCC Q26853567-4C70DA61-62D0-4D37-9DAA-7FD47D47793B Q26863577-AC8F1CB2-08E0-4808-8BF5-D52CE467E9BB Q26865149-6770AAB8-F038-47CF-A33A-1382CA8F0BE0 Q26991736-55D10362-1CC7-43E9-A882-993F9B0F729B Q26999888-4E3F2FB1-CBD7-4300-8A72-D908E30F4B4B Q27006010-97C975A3-6367-4CAA-8374-D37DFBA64CED Q27006839-5258A985-DD4D-43CB-BA91-D79DC7A2938A Q27014943-8D9B8757-5A31-4C2E-8884-1D94EF42B331 Q27021749-F213EAD4-1D99-4694-A923-863E2DE80822 Q27022720-70761336-637E-4377-8DCC-73B5377079B6 Q27023288-D5AB17F0-F7DB-42D3-A16D-B20BE4DD46A5 Q27025648-6FABDAB6-1EDD-451B-9DDB-46D76E2E10B7 Q27674674-4B97F8C8-EAD9-4838-871E-1A25EF53ED89 Q27675539-D1FD5EB6-884F-450C-B019-10FF389277B1 Q27675927-C0C3F7CD-79B0-400E-921E-614043ACFFA8

P2860

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

http://www.wikidata.org/entity/Q29617201

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

@ast

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

@en

type

label

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

@ast

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

@en

prefLabel

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

@ast

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

@en

P1433

Q29617201-381549D6-60D3-40FA-A8AF-BB5ECD607659

P1476

Q29617201-7E67F34C-28DD-45A5-85CF-89D91A3FCFE8

P2093

Q29617201-27DAB1A2-FF44-4430-926C-A308123EC564

Q29617201-3BE36AB5-F223-40FB-82C7-E1036B12B90C

Q29617201-3CC67E6F-0554-4A25-9CF2-3A4A354E488F

Q29617201-58F6A429-A3E1-492C-B0EC-8C6229FD5C80

Q29617201-6C9F9695-1E9D-45FD-8FA8-C2C318DE9601

Q29617201-70202CCE-F148-48F3-9FF2-196196904617

Q29617201-772FD5D1-4904-4E25-B2E7-90C672D871FC

Q29617201-9DE223B2-6578-4022-B85A-2EBFA2581CD0

Q29617201-9E861C1E-DC49-4603-9B12-8CEDFCA37771

Q29617201-B7F22127-19F4-4EB0-9F58-33A16C75118A

P2860

Q29617201-032D6389-8EC5-4A5B-94BE-66FFA0DF30A3

Q29617201-180CD476-4DA7-4273-834F-B9C69FA73BAA

Q29617201-217FB577-9F71-47A0-8337-A60FE0127F81

Q29617201-243F7F52-1ED4-4E49-AD5B-FB38B6601C8E

Q29617201-24A36C66-F2C4-41C9-A96B-232E76943D93

Q29617201-273F3662-1C87-4E85-9193-D9614E3F2EBE

Q29617201-29EE439B-D2EF-4465-8110-2273F57DD074

Q29617201-33955910-FF74-4001-B3A3-56C807EDAFA1

Q29617201-35ABFF59-415E-46B9-93DF-77DD45BDC93D

Q29617201-3738A34E-29C3-4D9F-B3DA-F5E40FB98789

P2888

Q29617201-C665A92C-935F-426B-806E-05778334CFCD

P304

Q29617201-5706E4B9-3220-4EE8-9E34-E05D6543AEAB

P31

Q29617201-39086486-C259-4C13-A96E-6677E20D66F4

P3181

Q29617201-59177BC9-6506-4967-988E-BEE1011924CE

P356

Q29617201-6EAB6E6D-DB92-4B87-B16B-7ABD49DFDB80

P407

Q29617201-22056F64-6C8F-45D8-9E42-AB8CC487BFFC

P433

Q29617201-C3C8A80D-D96B-423E-84C8-3CC521F695BF

P478

Q29617201-1EC2C339-5EC2-43AA-B9AC-045449A43E43

P50

Q29617201-09EE611E-41F3-4F7C-B96A-7ABD0B3FD75D

Q29617201-13828B6A-27A5-49EF-9E97-1817DE8FE709

Q29617201-3D09BEC2-E88E-4E2F-9CD2-943BAC7FE168

Q29617201-73E625A0-876D-4679-B3B3-7FC275734DD4

P577

Q29617201-F0E3B6F4-7A38-49E3-A065-51E9B625C6D4

P5875

Q29617201-66CF3DCB-B0C1-47D5-BF5C-895E7DE94178

P6179

Q29617201-5650EABA-C881-4574-A620-1D0A31A0A018

P698

Q29617201-0F0AE259-2410-4A52-B906-381D3D52CF82

P921

Q29617201-2C6FF15F-F2C3-4972-8D2C-7EC8F9315F51

Q29617201-3b5be224-4f01-0309-ee2a-1676fbd18e64

P932

Q29617201-A1C9D4E2-E8AF-4DF1-BD95-95CAB5994A86

P3181

P356

P1433

P1476

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

@en

P2093

Agustin Chicas

http://www.w3.org/2001/XMLSchema#string

Amy R Rappaport

http://www.w3.org/2001/XMLSchema#string

Christopher Johns

http://www.w3.org/2001/XMLSchema#string

Daniel Magoon

http://www.w3.org/2001/XMLSchema#string

Edward A Sison

http://www.w3.org/2001/XMLSchema#string

Eric Wang

http://www.w3.org/2001/XMLSchema#string

James C Mulloy

http://www.w3.org/2001/XMLSchema#string

James E Bradner

http://www.w3.org/2001/XMLSchema#string

Jun Qi

http://www.w3.org/2001/XMLSchema#string

Junwei Shi

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Selective inhibition of BET bromodomains

Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression

The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers

The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression

ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex

DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells

DNMT3A Mutations in Acute Myeloid Leukemia

P2888

P304

524-528

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1217522

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE10334

http://www.w3.org/2001/XMLSchema#string

P407

P433

7370

http://www.w3.org/2001/XMLSchema#string

P478

478

http://www.w3.org/2001/XMLSchema#string

P50

Christopher R. Vakoc

Harald Herrmann

P577

2011-08-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51545051

http://www.w3.org/2001/XMLSchema#string

P6179

1030076294

http://www.w3.org/2001/XMLSchema#string

P698

21814200

http://www.w3.org/2001/XMLSchema#string

P921

acute myeloid leukemia

P932

3328300

http://www.w3.org/2001/XMLSchema#string